Autoimmunity and the risk of myeloproliferative neoplasms
- PMID: 20053870
- PMCID: PMC2895049
- DOI: 10.3324/haematol.2009.020412
Autoimmunity and the risk of myeloproliferative neoplasms
Abstract
The causes of myeloproliferative neoplasm (MPN) are unknown. We conducted a large population-based study including 11,039 myeloproliferative neoplasm patients and 43,550 matched controls with the aim of assessing the associations between a personal history of a broad span of autoimmune diseases and subsequent risk of myeloproliferative neoplasm. We found a prior history of any autoimmune disease to be associated with a significantly increased risk of myeloproliferative neoplasms (odds ratio (OR)=1.2; 95% confidence interval (CI) 1.0-1.3; P=0.021). Specifically, we found an increased risk of MPNs associated with a prior immune thrombocytopenic purpura (2.9; 1.7-7.2), Crohn's disease (1.8; 1.1-3.0), polymyalgia rheumatica (1.7; 1.2-2.5), giant cell arteritis (5.9; 2.4-14.4), Reiter's syndrome (15.9; 1.8-142) and aplastic anemia (7.8; 3.7-16.7). The risk of myeloproliferative neoplasms associated with prior autoimmune diseases is modest but statistically significant. Future studies are needed to unravel the effects of these autoimmune diseases themselves, their treatment, or common genetic susceptibility.
Comment in
-
No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT3 predisposition SNP rs744166.Haematologica. 2010 Jul;95(7):1226-7. doi: 10.3324/haematol.2010.023390. Haematologica. 2010. PMID: 20595103 Free PMC article. No abstract available.
Similar articles
-
Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms.Leuk Res. 2016 Feb;41:27-35. doi: 10.1016/j.leukres.2015.11.017. Epub 2015 Dec 2. Leuk Res. 2016. PMID: 26718091
-
Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia.J Natl Cancer Inst. 2010 Apr 21;102(8):557-67. doi: 10.1093/jnci/djq043. Epub 2010 Feb 24. J Natl Cancer Inst. 2010. PMID: 20181958 Free PMC article.
-
Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia.J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30. doi: 10.1093/jnci/djj361. J Natl Cancer Inst. 2006. PMID: 16985251
-
Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms.Am J Hematol. 2012 Feb;87(2):175-82. doi: 10.1002/ajh.22212. Epub 2011 Nov 11. Am J Hematol. 2012. PMID: 22076943 Review.
-
GM-CSF Autoantibody-positive Pulmonary Alveolar Proteinosis with Simultaneous Myeloproliferative Neoplasm.Intern Med. 2017;56(4):435-439. doi: 10.2169/internalmedicine.56.6920. Epub 2017 Feb 15. Intern Med. 2017. PMID: 28202867 Free PMC article. Review.
Cited by
-
Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN.Cancers (Basel). 2020 Jul 24;12(8):2038. doi: 10.3390/cancers12082038. Cancers (Basel). 2020. PMID: 32722135 Free PMC article. Review.
-
Clinical spectrum and therapeutic management of auto-immune myelofibrosis: a nation-wide study of 30 cases.Haematologica. 2021 Mar 1;106(3):871-874. doi: 10.3324/haematol.2020.249896. Haematologica. 2021. PMID: 32467142 Free PMC article. No abstract available.
-
MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.Mediators Inflamm. 2015;2015:102476. doi: 10.1155/2015/102476. Epub 2015 Oct 28. Mediators Inflamm. 2015. PMID: 26604428 Free PMC article. Review.
-
Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.Mediators Inflamm. 2015;2015:606819. doi: 10.1155/2015/606819. Epub 2015 Oct 11. Mediators Inflamm. 2015. PMID: 26538830 Free PMC article. Review.
-
Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report.Case Rep Hematol. 2017;2017:3725089. doi: 10.1155/2017/3725089. Epub 2017 Jul 20. Case Rep Hematol. 2017. PMID: 28808591 Free PMC article.
References
-
- Swerdlov SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
-
- Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle. 2007;6(5):550–66. - PubMed
-
- SEER Cancer Statistics Review, 1975–2001. Bethesda, MD: National Cancer Institute; 2004.
-
- Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199–204. - PMC - PubMed
-
- Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14–22. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical